High TRA2B expression mediated by ncRNA correlates with adverse outcomes and tumor immune infiltration in hepatocellular carcinoma
Open Access
- 16 December 2025
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Abstract
Hepatocellular carcinoma (HCC) is one of the most frequent diagnosed malignancies globally with dismalprognosis and high mortality. Transformer 2 beta homolog (TRA2B), known as serine/arginine-rich splicing factor 10 (SRSF10), is a member of the serine/arginine (SR) protein superfamily that modulates gene expression by regulating mRNA splicing. The significance of TRA2B in cancer has received considerable attention in recent years, however, its specific role and molecular mechanisms in HCC remain unknown. This study aimed to analyze the expression of TRA2B in LIHC with the support of integrative bioinformatic analysis. The study conducted Kaplan-Meier and cox regression analyses and showed that the upregulated TRA2B was notably correlated with the dismal prognosis in HCC. TRA2B was identified as a potential proto-oncogene in HCC associated with poor prognosis. TRA2B expression in tumor tissues was found to be elevated using bioinformatics analysis. Following that, non-coding RNAs (ncRNA) related to TRA2B were extracted using series analysis. The CRNDE/LINC00511-miR-29c-3p axis was characterized as a potential upstream ncRNA-correlated signaling of TRA2B in HCC. Subsequently, the role of TRA2B in the tumor immune microenvironment (TIME) was investigated. In summary, this research provides novel insight into the potential role of TRA2B across various cancers and indicated that ncRNA-mediated overexpression of TRA2B is associated with the dismal prognosis in HCC.Keywords
This publication has 56 references indexed in Scilit:
- Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustionCancer Immunology, Immunotherapy, 2023
- TRA2: The dominant power of alternative splicing in tumorsHeliyon, 2023
- Management of Hepatocellular CarcinomaJAMA Surgery, 2023
- Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironmentJGH Open, 2021
- Suppressive Myeloid Cells Shape the Tumor Immune MicroenvironmentAdvanced Biology, 2021
- Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240Cancer, 2020
- Long non-coding RNA CRNDE promotes malignant progression of hepatocellular carcinoma through the miR-33a-5p/CDK6 axisJournal of Physiology and Biochemistry, 2020
- LINC00511 as a ceRNA promotes cell malignant behaviors and correlates with prognosis of hepatocellular carcinoma patients by modulating miR-195/EYA1 axisBiomedicine & Pharmacotherapy, 2020
- The Basis of OncoimmunologyCell, 2016
- A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?Cell, 2011